Pyxis Oncology, Inc.
PYXS
$1.14
-$0.05-4.20%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 40.52% | -67.76% | -22.55% | -431.36% | 79.12% |
| Total Depreciation and Amortization | 0.36% | -24.76% | 24.96% | -47.58% | 61.74% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -88.09% | 1,384.75% | 7.25% | -56.01% | 62.98% |
| Change in Net Operating Assets | 30.98% | -254.90% | -65.06% | 156.52% | -843.07% |
| Cash from Operations | -16.82% | -31.54% | -387.70% | 85.48% | -35.77% |
| Capital Expenditure | -- | -- | -- | 100.00% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -40.65% | 333,312.50% | -300.00% | 100.02% | -278.56% |
| Cash from Investing | -40.65% | 333,312.50% | -300.00% | 100.02% | -280.86% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | 6,015.03% | -99.73% | 213,629.63% |
| Repurchase of Common Stock | 99.97% | -764,900.00% | 97.67% | 78.06% | -276.92% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 200.00% | -- | -- | -- |
| Cash from Financing | -100.00% | -96.98% | 1,404.55% | -99.81% | 230,144.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -190.52% | 156.97% | -349.98% | -115.81% | 462.36% |